Clinical Trial Detail

NCT ID NCT00602329
Title MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Pennsylvania
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Bevacizumab

Age Groups: adult

No variant requirements are available.